FDA to reconsider shock rejection of cell therapy Ebvallo. Could uniQure be next?

After a surprise rejection in January, the FDA has agreed to reconsider a T-cell therapy based on the same single-arm trial that the agency had previously found problematic. The case could reignite investors’ hope of a potential reversal for uniQure's high-profile gene therapy, too.

By FiercePharma · May 10, 2026 · via FiercePharma

FDA to reconsider shock rejection of cell therapy Ebvallo. Could uniQure be next?

Image: FiercePharma

This is an aggregated industry headline. Read the full story at FiercePharma →

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.